Last update March 19, 2020
A peripheral inhibitor of the enzyme dopa-decarboxylase which transforms levodopa into dopamine.
Its only medical use is to associate it with levodopa in the treatment of Parkinson's disease in order to block the peripheral effects of levodopa by becoming dopamine (nausea, vomiting, arrhythmias) and allowing more levodopa to reach the brain and levodopa can be given at a lower dose.
Carbidopa does not cross the blood-brain barrier, so it has no effects at the level of the central nervous system.
Oral administration 3 to 4 times a day.
Since the last update we have not found published data on its excretion in breastmilk.
Its wide volume of distribution and short half-life make it unlikely it will transfer into breastmilk in significant amounts.
Carbidopa increases prolactin levels (Masturzo 1979, Brown 1976) and inhibits the suppressive effects of levodopa on prolactin (Camanni 1978).
We do not have alternatives for Carbidopa.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM